Get alerts of updates about «Coronavirus vaccine from Novavax will be available in week 10»
You have subscribed to alerts about:
Coronavirus vaccine from Novavax will be available in week 10
Nuvaxovid is a protein-based vaccine and is based on a more traditional vaccine technology than the mRNA vaccines. Nuvaxovid received conditional approval from the European Medicines Agency (EMA) at the end of December 2021 for use from the age of 18 years. The vaccine has been shown to provide good protection against COVID-19 disease.
“It has been decided to make a smaller number of doses of Nuvaxovid available in Norway so that those who want to use this vaccine can do so,” says Sara Viksmoen Watle, Senior Physician at the Norwegian Institute of Public Health.
The need for this vaccine is assumed to be low in Norway, and a significant part of the planned delivery will be donated to other countries.
Watle believes that the current supporting knowledge does not provide any basis to prefer Nuvaxovid over mRNA vaccines for the primary vaccination series or for booster doses. However, Nuvaxovid may be relevant for those people who want to use a vaccine other than an mRNA vaccine.